Sun Pharma Inds.
Ticker >

Sun Pharma Inds. share price

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA BSE: 524715 SECTOR: Pharmaceuticals & Drugs  341k   2k   463

1525.00
+2.45 (0.16%)
BSE: 19 Apr 04:01 PM

Price Summary

Today's High

₹ 1528.9

Today's Low

₹ 1502.15

52 Week High

₹ 1638.7

52 Week Low

₹ 922.55

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 365898.58 Cr.

Enterprise Value

₹ 373069.97 Cr.

No. of Shares

239.93 Cr.

P/E

377.31

P/B

14.77

Face Value

₹ 1

Div. Yield

0.76 %

Book Value (TTM)

₹  103.23

CASH

₹ 421.28 Cr.

DEBT

₹ 7592.67 Cr.

Promoter Holding

54.48 %

EPS (TTM)

₹  4.04

Sales Growth

33.53%

ROE

7 %

ROCE

7.28%

Profit Growth

1790.89 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Sun Pharmaceutical Industries Ltd.

Molxvir Gloeye Prazopress Pantocid Predmet Garlic Pearls REVITAL VOLINI PEPFIZ Diamox Deslor Cepodem Colvac Livcare Montek Mox CV Nexito

Index Presence

The company is present in 35 Indices.

NIFTY100WEIGHT

Nifty100 Equal Weight
29262.05
  21.6499999999978 (0.0740413947825536%)

NIFTYEQWGT

NIFTY50 Equal Weight
27762.95
  114.299999999999 (0.413401739325425%)

NFTALLO30

NIFTY Alpha Low-Volatility 30
25623.6
  -30.0500000000029 (-0.117137327436845%)

NIFTY100

Nifty 100
22859.8
  119.599999999999 (0.52594084484745%)

NIFTY

Nifty 50
22147
  151.150000000001 (0.687175080753866%)

NIFTY500

Nifty 500
20385.2
  60.5 (0.297667370244081%)

NIFTYPHARMA

Nifty Pharma
18404.6
  -121.150000000001 (-0.653954630716713%)

NT100LOW30

Nifty100 Low Volatility 30
17551.35
  -13.1000000000022 (-0.0745824662884531%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14099.7
  15.1000000000004 (0.107209292418675%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
14038.4
  3 (0.0213745244168395%)

NIFTYMFG

Nifty Manufacturing
12473.3
  10.75 (0.0862584302570468%)

NIFTY200

Nifty 200
12325.85
  43.1499999999996 (0.35130712302669%)

NIFTYHEALTH

Nifty Healthcare Index
11625.45
  -46.75 (-0.400524322749785%)

NIFTYTOTALMCAP

Nifty Total Market index
11455.35
  32.3999999999996 (0.283639515186529%)

NI15

NI15
10595.6
  27.9500000000007 (0.264486427919186%)

NIFTY100ESG

NIFTY100 ESG
4314.05
  14.4499999999998 (0.336077774676702%)

NIFTYLOWVOL

Nifty Low Volatility 50
21760.16
  32.3600000000006 (0.148933624204939%)

SENSEX

S&P Bse Sensex
73088.33
  599.339999999997 (0.826801421843504%)

BSE HC

S&P Bse Healthcare
34422.67
  -152.889999999999 (-0.442190958006172%)

BSE500

S&P Bse 500
32199.48
  102.119999999999 (0.318157007305264%)

SNSX50

S&P Bse Sensex50
23260.5
  158.98 (0.688179825396773%)

BSE100

S&P Bse 100
23199.58
  126.700000000001 (0.549129540828885%)

BSE200

S&P Bse 200
10088.94
  39.3299999999999 (0.391358470627212%)

LMI250

S&P Bse 250 LargeMidCap
9560.57
  34.7999999999993 (0.365324797890354%)

ALLCAP

S&P Bse Allcap
9386.8
  27.2999999999993 (0.291682247983327%)

LRGCAP

S&P Bse LargeCap
8654.1
  45.2299999999996 (0.525388349458167%)

BSE100LARGECAPTMC

S&P Bse 100 LargeCap TMC
8292.74
  43.8099999999995 (0.531099184985195%)

GREENEX

S&P Bse Greenex
6535.05
  51.8299999999999 (0.799448422234628%)

CARBONEX

S&P Bse Carbonex
3776.69
  22.3699999999999 (0.595846917684151%)

SPBSLVIP

S&P Bse Low Volatility
1689.48
  6.67000000000007 (0.396360848818356%)

MFG

S&P Bse Manufacturing
982.41
  2.83999999999992 (0.289923129536418%)

S&PDIVSTABLE

S&P Bse Dividend Stability
950.91
  -1.95000000000005 (-0.204647062527552%)

ESG100

S&P Bse 100 ESG Index
363.5
  3.06999999999999 (0.851760397303214%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
9508.32
  33.8799999999992 (0.357593694191949%)

SHA500

S&P Bse 500 Shariah
8943.52
  -13.3099999999995 (-0.148601681621729%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year33.53%
3 Year18.42%
5 Year18.3%

Profit Growth

1 Year1790.89%
3 Year-19.25%
5 Year40.79%

ROE%

1 Year7%
3 Year3.3%
5 Year5.42%

ROCE %

1 Year7.28%
3 Year4.31%
5 Year5.89%

Debt/Equity

0.3197

Price to Cash Flow

721.58

Interest Cover Ratio

4.68725909610742

CFO/PAT (5 Yr. Avg.)

1.59033690509173

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 54.48 2.05
Dec 2023 54.48 2.44
Sep 2023 54.48 2.44
Jun 2023 54.48 2.29
Mar 2023 54.48 1.78
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 18.4219455384214% for the Past 3 years.
  • Company’s PEG ratio is 0.210659867349458.
  • The company has an efficient Cash Conversion Cycle of -18.6467010455568 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.59033690509173.
  • The company has a high promoter holding of 54.48%.

 Limitations

  • The company has shown a poor profit growth of -19.2509385495058% for the Past 3 years.
  • Company has a poor ROE of 3.29651051069589% over the past 3 years.
  • Company has a poor ROCE of 4.31020370520073% over the past 3 years
  • Tax rate is low at 2.89078429683237.
  • The company is trading at a high PE of 377.31.
  • The company is trading at a high EV/EBITDA of 57.5595.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 4645.75 5948.22 4466.07 5096.21 5073.75
Total Expenditure 3652.97 3587.57 3517.31 3719.28 3866.43
Operating Profit 992.78 2360.65 948.76 1376.93 1207.32
Other Income 74.63 120.3 163.54 115.93 228.48
Interest 130.89 161.45 157.94 193.63 214.92
Depreciation 430.44 411.98 415.27 392.71 399.6
Exceptional Items 0 -2937.79 -149.21 0 -69.81
Profit Before Tax 506.08 -1030.27 389.88 906.52 751.47
Tax 19.35 -9.45 9.24 17.89 30.16
Profit After Tax 486.73 -1020.82 380.64 888.63 721.31
Adjusted EPS (Rs) 2.03 -4.25 1.59 3.7 3.01

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 10303.21 12531.93 14116.05 15585.98 20812.14
Total Expenditure 8561.66 9820.28 11859.04 12917.42 14389.54
Operating Profit 1741.55 2711.65 2257.01 2668.56 6422.6
Other Income 1286.15 1510.92 192.07 1196.88 329.29
Interest 540.92 408.01 267.52 388.1 472.18
Depreciation 552.95 561.56 1236.43 1349.95 1600.87
Exceptional Items -1214.38 0 -89.56 -1820.53 -2937.79
Profit Before Tax 719.45 3253 855.57 306.86 1741.05
Tax -97.15 41.86 13.17 406.85 50.33
Net Profit 816.6 3211.14 842.4 -99.99 1690.72
Adjusted EPS (Rs.) 3.4 13.38 3.51 -0.42 7.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 239.93 239.93 239.93 239.93 239.93
Total Reserves 22603.68 24156.29 26698.54 24348.02 23508.43
Borrowings 1422.5 1256.69 5300.02 4865.64 7586.73
Other N/C liabilities 514.09 1890.56 1928.04 1498.21 1642.04
Current liabilities 13271.83 11203.74 9951.33 10105.83 8365.44
Total Liabilities 38052.03 38747.21 44117.86 41057.63 41343.19
Assets
Net Block 4978.42 5228.74 9668.79 9712.78 8711.67
Capital WIP 456.25 384.35 459.2 358.94 328.87
Intangible WIP 186.29 212.26 631.18 469.7 524.04
Investments 17656.16 16966.65 15506.2 15355.83 12416.14
Loans & Advances 3592.57 4013.14 5120.85 5451.94 2882.26
Other N/C Assets 12.57 0.95 1.56 4.69 36.46
Current Assets 11169.77 11941.12 12730.08 9703.75 16443.75
Total Assets 38052.03 38747.21 44117.86 41057.63 41343.19
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 719.45 3253 855.57 306.86 1741.05
Adjustment 448.66 -217.09 1717.87 1266.29 4823.4
Changes in Assets & Liabilities 111.5 -1393 -2752.28 3903.67 -5625.38
Tax Paid -37.43 -337.06 -237.67 2159.54 -431.99
Operating Cash Flow 1242.18 1305.85 -416.51 7636.36 507.08
Investing Cash Flow 431.37 1483.04 1452.47 -2697.04 -685.64
Financing Cash Flow -1468.59 -2871.15 -999.73 -4870.85 169.31
Net Cash Flow 204.96 -82.26 36.23 68.47 -9.25

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 54.48 54.48 54.48 54.48 54.48
aalok dilip shanghvi 0.12 0.12 0.12 0.12 0.12
aditya medisales limited 1.67 1.67 1.67 1.67 1.67
dilip. s. shanghvi - - - - 9.60
raksha s.valia 1.20 - 1.20 1.20 1.20
shanghvi family & friends... 0.05 0.05 0.05 0.05 0.05
shanghvi finance private ... 40.30 40.30 40.30 40.30 40.30
sudhir v. valia 0.60 - - - 0.60
unimed investments limite... 0.43 0.43 0.43 0.43 0.43
vibha dilip shanghvi 0.37 0.37 0.37 0.37 0.37
vidhi dilip shanghvi 0.12 0.12 0.12 0.12 0.12
dilip shantilal shanghvi - - 9.60 9.60 -
kumud shantilal shanghvi 0.01 0.01 0.01 0.01 -
sudhir vrundavandas valia... - - - 0.60 -
sudhir vrundavan valia - - 0.60 - -
dilip shanghvi - 9.60 - - -
raksha valia - 1.20 - - -
sudhir valia - 0.60 - - -
dilip.s.shanghvi 9.60 - - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 45.52 45.52 45.52 45.52 45.52
government pension fund g... 1.08 1.15 1.03 1.05 1.04
icici prudential value di... 3.06 - 3.44 3.39 3.15
investor education and pr... - - - 0.12 0.12
life insurance corporatio... 3.28 3.11 2.91 2.84 2.92
llp 0.25 0.25 0.20 0.20 0.27
sbi nifty 50 etf 2.52 - 2.38 2.38 2.27
government of singapore - - 1.20 1.15 -
nps trust- a/c sbi pensio... - 1.07 1.13 1.18 -
investor education and pr... 0.10 0.10 0.10 - -
icici mutual funds - 3.37 - - -
sbi funds - 2.47 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

USFDA issues OAI status to Sun Pharmaceutical Industries’ Dadra facility12 Apr 2024, 11:20AM Sun Pharmaceutical Industries informs about details of loss of certificate23 Mar 2024, 1:04PM Sun Pharmaceutical Industries informs about press release19 Mar 2024, 10:12AM Sun Pharmaceutical Industries informs about loss of share certificate16 Mar 2024, 12:25PM Sun Pharmaceutical Industries informs about investor presentation14 Mar 2024, 5:20PM Sun Pharma’s arm recalls around 55,000 bottles of generic drug from US market11 Mar 2024, 11:51AM Sun Pharmaceutical to acquire 16.33% stake in Surgimatix21 Feb 2024, 12:00PM Sun Pharmaceutical Industries informs about press release12 Feb 2024, 1:22PM Sun Pharma included in S&P Global Sustainability Yearbook 202412 Feb 2024, 11:42AM Sun Pharmaceutical Industries’ arm incorporates wholly-owned subsidiary6 Feb 2024, 10:15AM Sun Pharmaceutical Industries reports 17% rise in Q3 consolidated net profit31 Jan 2024, 5:17PM Sun Pharma Inds. - Quaterly Results31 Jan 2024, 2:13PM Sun Pharma Inds. - Quaterly Results31 Jan 2024, 2:13PM Sun Pharma Inds. - Quaterly Results31 Jan 2024, 2:13PM Sun Pharmaceutical to acquire remaining stake in Taro Pharmaceutical Industries18 Jan 2024, 2:14PM Sun Pharmaceutical Industries informs about acquisition18 Jan 2024, 9:52AM Sun Pharmaceutical Industries inks pact with Bayer17 Jan 2024, 2:41PM Sun Pharmaceutical Industries informs about loss of share certificates5 Jan 2024, 5:05PM Sun Pharmaceutical Industries acquires 100% stake in Libra Merger3 Jan 2024, 11:56AM Sun Pharmaceutical Industries to acquire 16.7% shares in Lyndra Therapeutics, Inc19 Dec 2023, 9:58AM Sun Pharma’s arm recalls 96,192 bottles of Liothyronine Sodium Tablets in US18 Dec 2023, 2:23PM Sun Pharmaceutical Industries informs about disclosure 16 Dec 2023, 11:02AM Sun Pharma's specialty product Ilumetri included in China's national reimbursement drug list13 Dec 2023, 2:39PM Sun Pharmaceutical Industries informs about update12 Dec 2023, 10:10AM Sun Pharmaceutical Industries informs about disclosure 6 Dec 2023, 9:42AM Sun Pharma’s arm enters into licensing agreement with Aclaris Therapeutics, Inc.6 Dec 2023, 9:19AM Sun Pharmaceutical Industries reports 6% rise in Q2 consolidated net profit1 Nov 2023, 2:22PM Sun Pharma Inds. - Quaterly Results1 Nov 2023, 1:23PM Sun Pharma Inds. - Quaterly Results1 Nov 2023, 1:23PM Sun Pharma Inds. - Quaterly Results1 Nov 2023, 1:23PM Sun Pharmaceutical Industries informs about press release 30 Oct 2023, 4:46PM Sun Pharma inks licensing agreement with Zydus Lifesciences for co-marketing of Desidustat30 Oct 2023, 11:08AM Sun Pharma’s arm recalls 144 bottles of anti-depression drug from US market20 Oct 2023, 12:00PM Sun Pharmaceutical Industries submits analyst meet intimation17 Oct 2023, 4:29PM Sun Pharmaceutical Industries informs about press release16 Oct 2023, 1:05PM Sun Pharma’s arm recalling 69,707 cartons of Cequa from US market9 Oct 2023, 12:40PM Sun Pharmaceutical Industries informs about press release6 Oct 2023, 10:12AM Sun Pharmaceutical Industries to acquire around 37.76% stake in EzeRx6 Oct 2023, 10:11AM Sun Pharma’s arm to acquire balance 25% outstanding shares in Sun Pharma de Mexico29 Sep 2023, 11:42AM Sun Pharma’s arm launches WINLEVI in Canada27 Sep 2023, 3:08PM Sun Pharmaceutical Industries informs about loss of share certificates25 Sep 2023, 5:27PM Sun Pharmaceutical Industries informs about loss of share certificates21 Sep 2023, 5:23PM Sun Pharmaceutical Industries informs about press release14 Sep 2023, 12:25PM Sun Pharmaceutical’s arm enters into license agreement with Pharmazz Inc14 Sep 2023, 11:40AM Sun Pharma aiming to spend 7-8% of sales on R&D in current fiscal29 Aug 2023, 11:27AM Sun Pharmaceutical Industries informs about loss of share certificate 19 Aug 2023, 10:05AM Sun Pharmaceutical Industries informs about analyst meet16 Aug 2023, 2:40PM Sun Pharmaceutical Industries informs about press release3 Aug 2023, 3:43PM Sun Pharmaceutical Industries reports marginal fall in Q1 consolidated net profit3 Aug 2023, 2:28PM Sun Pharma Inds. - Quaterly Results3 Aug 2023, 2:05PM

Sun Pharma Inds. Stock Price Analysis and Quick Research Report. Is Sun Pharma Inds. an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sun Pharma Inds. and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Sun Pharma Inds. cash from the operating activity was Rs 507.08 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sun Pharma Inds. has a Debt to Equity ratio of 0.3197 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sun Pharma Inds. , the EPS growth was 1791.07271418287 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sun Pharma Inds. has OPM of 30.8598731317395 % which is a good sign for profitability.
     
  • ROE: Sun Pharma Inds. have a poor ROE of 6.99565192295399 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Sun Pharma Inds. is Rs 1522.8. One can use valuation calculators of ticker to know if Sun Pharma Inds. share price is undervalued or overvalued.
Last Updated on:
Brief about Sun Pharma Inds.

Sun Pharmaceutical Industries Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Sun Pharmaceutical Industries Ltd. is a leading pharmaceutical company in India, providing a wide range of products and services to its customers. In this article, we will analyze Sun Pharmaceutical Industries Ltd. from a stock market perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Sun Pharmaceutical Industries Ltd. Share Price:

The share price of Sun Pharmaceutical Industries Ltd. is an important indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s share price and identify any trends or patterns. Sun Pharmaceutical Industries Ltd.'s share price has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharmaceutical Industries Ltd. Balance Sheet:

Sun Pharmaceutical Industries Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and other assets. Liabilities include borrowings, trade payables, and other liabilities. Equity includes share capital, reserves, and surplus. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s balance sheet and identify any red flags. The company's balance sheet has remained strong over the years, with a healthy mix of assets and liabilities.

Sun Pharmaceutical Industries Ltd. Annual Report:

Sun Pharmaceutical Industries Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Investors can download Sun Pharmaceutical Industries Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Dividend:

Sun Pharmaceutical Industries Ltd. pays dividends to its shareholders on a regular basis. Dividends are a portion of the company's profits that are distributed to shareholders. Investors can use our pre-built screening tools to track Sun Pharmaceutical Industries Ltd.'s dividend history and dividend yield. The company has a consistent track record of paying dividends to its shareholders, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Quarterly Results:

Sun Pharmaceutical Industries Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Sun Pharmaceutical Industries Ltd. Stock Price:

Sun Pharmaceutical Industries Ltd.'s stock price is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Investors can use our pre-built screening tools to track Sun Pharmaceutical Industries Ltd.'s stock price and identify potential buying opportunities. The stock price of Sun Pharmaceutical Industries Ltd. has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharmaceutical Industries Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Sun Pharmaceutical Industries Ltd. has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharmaceutical Industries Ltd. News:

Keeping up to date with the latest news about Sun Pharmaceutical Industries Ltd. is important for investors. Our website provides the latest news about Sun Pharmaceutical Industries Ltd. from various sources such as financial news websites and social media. Investors can use this information to make informed investment decisions.

Sun Pharmaceutical Industries Ltd. Concall:

Sun Pharmaceutical Industries Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Investors can listen to Sun Pharmaceutical Industries Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Sun Pharmaceutical Industries Ltd. Transcripts:

Transcripts of Sun Pharmaceutical Industries Ltd.'s concalls are available on our website. Investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Investor Presentations:

Sun Pharmaceutical Industries Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Investors can download Sun Pharmaceutical Industries Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Sun Pharmaceutical Industries Ltd.'s promoters include various entities that hold a significant stake in the company. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Sun Pharmaceutical Industries Ltd. are relatively stable, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Shareholders:

Sun Pharmaceutical Industries Ltd. has a large number of shareholders, including institutional investors and individual investors. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Sun Pharmaceutical Industries Ltd. is diverse, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Sun Pharmaceutical Industries Limited ROCE

Sun Pharmaceutical Industries Limited is a leading pharmaceutical company. Return on Capital Employed (ROCE) is an important financial ratio that helps investors understand how efficiently a company is utilizing its capital. The ROCE of Sun Pharmaceutical Industries Limited can be found in the financials table or ratio section above.

Sun Pharmaceutical Industries Limited EBITDA

EBITDA, or Earnings Before Interest, Taxes, Depreciation, and Amortization, is a key metric for analyzing the profitability of a company. The EBITDA of Sun Pharmaceutical Industries Limited can be found in the financials table or ratio section above.

Sun Pharmaceutical Industries Limited DPS

DPS, or Dividends Per Share, is an important factor for investors interested in dividend income from a company. The DPS of Sun Pharmaceutical Industries Limited can be found in the financials table or ratio section above.

Sun Pharmaceutical Industries Limited EPS

EPS, or Earnings Per Share, provides insights into a company's profitability on a per-share basis. The EPS of Sun Pharmaceutical Industries Limited can be found in the financials table or ratio section above.

Please note that detailed data for these ratios can be obtained in the above financials table or ratio section.

Read More
X